RHYTHM PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M | $0 | $0 |
| Cost of Revenue | — | $19.5M | $13.4M | $9.3M | $2.1M | $599.0K | — | — |
| Gross Profit | — | $170.3M | $116.8M | $68.1M | $21.5M | $2.6M | — | — |
| Gross Margin | — | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $167.3M | $238.0M | $135.0M | $108.6M | $104.1M | $90.5M | $109.5M |
| SG&A Expense | — | $194.9M | $144.3M | $117.5M | $92.0M | $68.5M | $46.1M | $36.6M |
| Operating Income | — | $-192.0M | $-265.5M | $-184.4M | $-179.2M | $-170.1M | $-136.6M | $-146.0M |
| Operating Margin | — | -101.2% | -204.0% | -238.1% | -757.9% | -5,391.9% | — | — |
| Interest Expense | — | — | — | $13.9M | $5.2M | — | — | — |
| Pretax Income | — | $-196.0M | $-260.3M | $-184.1M | $-181.1M | $-69.6M | — | — |
| Income Tax Expense | — | $497.0K | $346.0K | $564.0K | — | — | — | — |
| Net Income | — | $-196.5M | $-260.6M | $-184.7M | $-181.1M | $-69.6M | $-134.0M | $-140.7M |
| Net Margin | — | -103.6% | -200.3% | -238.5% | -766.2% | -2,207.1% | — | — |
| EPS (Basic) | — | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 |
| EPS (Diluted) | — | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 |
| Shares Outstanding (Basic) | 68.3M | 65.0M | 61.0M | 57.7M | 52.1M | 49.6M | 44.1M | 36.4M |
| Shares Outstanding (Diluted) | 68.3M | 65.0M | 61.0M | 57.7M | 52.1M | 49.6M | 44.1M | 36.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |